{"name":"Avalo Therapeutics, Inc.","slug":"avalo-therapeutics-inc","ticker":"","exchange":"","domain":"avalo.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"AEVI-007","genericName":"AEVI-007","slug":"aevi-007","indication":"Other","status":"phase_1"},{"name":"AVTX-009 Regimen 1","genericName":"AVTX-009 Regimen 1","slug":"avtx-009-regimen-1","indication":"Other","status":"phase_2"},{"name":"AVTX-009 Regimen 2","genericName":"AVTX-009 Regimen 2","slug":"avtx-009-regimen-2","indication":"unknown","status":"phase_2"},{"name":"FP01","genericName":"FP01","slug":"fp01","indication":"Other","status":"phase_2"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AVTX-002","genericName":"AVTX-002","slug":"avtx-002","indication":"Type 2 diabetes","status":"phase_2"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"CERC-301","genericName":"CERC-301","slug":"cerc-301","indication":"Moderate to severe psoriasis","status":"phase_2"}]}],"pipeline":[{"name":"AVTX-002","genericName":"AVTX-002","slug":"avtx-002","phase":"phase_2","mechanism":"AVTX-002 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"AEVI-007","genericName":"AEVI-007","slug":"aevi-007","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AVTX-009 Regimen 1","genericName":"AVTX-009 Regimen 1","slug":"avtx-009-regimen-1","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AVTX-009 Regimen 2","genericName":"AVTX-009 Regimen 2","slug":"avtx-009-regimen-2","phase":"phase_2","mechanism":"AVTX-009 Regimen 2 is a small molecule that targets the molecular target.","indications":["unknown"],"catalyst":""},{"name":"CERC-301","genericName":"CERC-301","slug":"cerc-301","phase":"phase_2","mechanism":"CERC-301 is a monoclonal antibody targeting CD28 to modulate T-cell activation.","indications":["Moderate to severe psoriasis","Moderate to severe atopic dermatitis"],"catalyst":""},{"name":"FP01","genericName":"FP01","slug":"fp01","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE9ZMEJ3MUVHWEtwV05ucjdFWGRkOV9SQTNxOTNPSHZjOUZaem83MXRYWkJmZF8xdlBtNnkzLTltaE1MeG1uQV9Dak9Uc3JseUN1bi1kM0ZqNVU1MC1aOG9hckx3?oc=5","date":"2026-04-07","type":"pipeline","source":"Yahoo Finance UK","summary":"Avalo Therapeutics, Inc. (AVTX) stock price, news, quote and history - Yahoo Finance UK","headline":"Avalo Therapeutics, Inc. (AVTX) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTFBtQ0pRTFJyLVlMZ1FwYWpWYnNZc0RLeUJyY2N6YVhNZzRVRUhIQUxWcjdyOWZrdUF0UmxkNkJVWlFXYnhHMlFBanZlMjl6UFRFUWtLeXl6ZktaSEZXMkHSAWNBVV95cUxNNVNiTElHMV9WSEJWUVZjTHBlV1hVOTIzQzVwQ1BYZVN5Vi1zcGJCX2NxYWtyclNvYTQ1MFotS200bDFPVWJqVXhYUGNELTAxN2NRcHZEcFdWZFpBWjRTRldHa3c?oc=5","date":"2026-04-06","type":"pipeline","source":"Bitget","summary":"Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics, and Avalo Therapeutics - Bitget","headline":"Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therap","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wJBVV95cUxQcEx1cUZ4UzJjN1ZKaUZFaGY1ZXA5WVZ5NklIaVowUEg0OTJ0U0pXeExJOXRLaTVabk0tandGVWN5cUdRS1VVT3h3LWx0T1hpQmJpSkV1TnRzU1g2NXhaLUdVTmdqMjJCemJHUElxYWFyVG1aMUVUaHZ6amw3Q2ZCOTFyX1kxdGIwdk56bjdxaUczRXZndlQtaGh6T3JTVzJBVjRJLU14RGlYWURVWTR0SFNVbE52SURMdUVyQ1lkZXJ2N2piVUlFczhiQTQxd3pIaS1aYU1VcEZOcUE1S3ZtU3BMeDJwUGhJMnhMTmtDZnB3OXRkNWlBamtibVlWNzROVTdtOVZ1d0tnR2hPcm1UUHNQSTJ3akVybm1HazZWbUp6a29EcDlaZDBNc1BjSXVtU2gwTWd4R2FmWFdGNEVqQ0FuWWZ6MHhLeUFsbmNGbXJSSVE?oc=5","date":"2026-04-06","type":"pipeline","source":"The Globe and Mail","summary":"Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics - The Globe and Mail","headline":"Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Ther","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygJBVV95cUxQWTJVTGh0ejN2YjM1TlN0dzlINUI2X0dubnVSWHdzTGxaZFBRM3RqNm14LWdMWERyamxIbW1YTHZLRWhpbDhDR3dFNHIwSWxMWGZOQXBweEpPdG9qakYwNUoySzZZN0lQQlV2a1FDX0Z0ZmxDYlREY0tmSVpYYkR6YjY4OWlseUFTWmF3VG1fMElGeXNTczZsTEFFdFpOTy1JN3ZJMnd5NGFTNXpaeXRINnNkWVBTVW1zbUlwZGNROUZnR0xvcXpLcFh1dXdmMEFMUGJYU2dMNV9Zdm9VcktZMUU4WUQzZmxrcEdqVXRQT1RtbWhlS1NZYTk0WmVqWUdZakhvZGIwaVdMVU84MDAyNkVZOFhlNkRFODR5T2ZzTzQzOWpPMjF0cktlcDVZNl9Nc0hkbWc5ZldWZm1iSlVNaWx3aURiWF9lUnc?oc=5","date":"2026-03-26","type":"pipeline","source":"Barchart.com","summary":"Asthma Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma - B","headline":"Asthma Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | GlaxoSmithKline, AB Science, Areteia The","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBFdUFXZUczRzlybDFZMFJVN2xyTm4zNFFpTWRQWFQ2R3pQVHpDbTFTbVRSenA1UW9pM25iNGhjNGZERlBUZi1JRjYxQTJmTHI1ZTYwcmF4MEppWUEyY1Z4SUZXZjcwZWRweUhIOC13?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Avalo Therapeutics Inc (AVTX) - Stock Titan","headline":"If You Invested $1,000 in Avalo Therapeutics Inc (AVTX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPSU91N1pfTWNnUzZuVjZiRjV3QTUxZnRiclF1ZWxtYWlLby0zWC1STGNXcGdKX3B2MlR2UkRQelRGQjF6cmlsMlBkdHhXU2hmR0RCTkRsaE9vZWtHbVUxMHhyT3VDT0dkRlBJWF82VmtWa19sM1JKOFEzWFRQXzVhME5OVjhGVnhsaWdKYWpR?oc=5","date":"2026-02-11","type":"pipeline","source":"The Pharma Letter","summary":"Helus Pharma appoints Michael Cola as CEO - The Pharma Letter","headline":"Helus Pharma appoints Michael Cola as CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxNcnVMNFI3VEtZTS1JS01LbmtNRzFkc0RKMnRQbHVyNWk3LTBaTFd4azdCUDNYQjh5STd3RzZDZ0dRa2pWRjdfUnpuUVVxekdBNlQ0UzNNMFgwX2Zqcm9YVTZmdXpnWEFDUU11RTItV1RseXZWb2tTUG1aOS1IUkFJc0ZBOUMxZk5pbTd1UnBZVWhGV0J4NDlFdE9jcXdFYjd3X2J0RlVheXVZNmM3WkVPVmZHQlM5UFRBT3BRa0J1NEg2b2g4TTEyd3Ixb2txYXUwSTVLSi1uMlhzb1hoWUZJeE03T3pxc2_SAewBQVVfeXFMT3QwN0pjU3d5S0Qwd3hEWERNanIyXzN5Vm5RYjd1Zk03Mm9ySXo1Y2RFRVpzYUNEWm8wWlVodUdSSkN0cUdWYndQWUFGVFAxRHR6d3oxZVZEM3B0SkozT29jc1pXczRtVFhMRW1jV2JvdE5kZWR6REdZTGx6Z3RrcTkwQ3lVU1VDdG5JbnpQTkhFVm5zeUtSazl1d2xqLWg1bzd1amI3a2lYSHVhSDFEZ1BweVR2NUhkZVJ0NG10Wm5RYUZURlJMYm4wS0tSZ2RZeWhEWF9GS2NtVlpIeU5kUWN2QU91SDA3bUdGNDM?oc=5","date":"2025-09-16","type":"earnings","source":"simplywall.st","summary":"Avalo Therapeutics, Inc.'s (NASDAQ:AVTX) institutional investors lost 11% over the past week but have profited from longer-term gains - simplywall.st","headline":"Avalo Therapeutics, Inc.'s (NASDAQ:AVTX) institutional investors lost 11% over the past week but have profited from long","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPaFAydmJzVDhXZWhKODVLT1VVQ05aWmFrTGpITktiRHN6YTFLaVpVNkRrZV9XNm5jeGg0NFI3LS15S0VzMHQ2ZDRucWh3dUJ3ZlZwUm5PdndCMHZHRGxTZDVfU25uLU16UVVydlQ1Nkx2MU0zd0FoMUd6MkVEdnlFeGlWU2dZRHJiRmc2U2M2eEpVYWZhSkF6aTF3?oc=5","date":"2025-01-03","type":"pipeline","source":"Fierce Biotech","summary":"Vincerx acquisition leads to C-suite shake-up—Chutes & Ladders - Fierce Biotech","headline":"Vincerx acquisition leads to C-suite shake-up—Chutes & Ladders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxQUlBEN2JQMkVlejVsUDE0d0pQcXhDTHBHdE1nMmhzTVNERFBfTDkzWW83Yi1ZZEpBbHowUjA1S0VpNnJ2NXZnUHRJY09NUDVxZnp2WFNxc1I2Q0x3dTFldXhFNm5JUDR5MlA4a0tDeTUxYm5WYTZMVzZUczJHYjBHbDFFaDRiTDZTSlJNRzFnbHBjNUYwNkR3ejJGa3AweDlpeVdhdk5ucGJmSHctSTdHS3g5N2lMYU1fMDB3TlYtUlBScG4zYUI4bk5LQjVlaGt3blZ5OWRfdkVCY2NFcWYtZ1UxVGxrZWJtZExQSGxFYUN4c1ZSQWhaZkxhT1M1RXRudlNuRXNlMXQ3MzFPMkZTeFRvS3VVaHprWlpsazd1akZOUQ?oc=5","date":"2024-11-06","type":"trial","source":"PR Newswire","summary":"Severe Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire","headline":"Severe Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQdjZMNlUzdzNYSmNfRm1rcGoyczZUNm5QVDFKZ3pFYUxGblpzZHFFeS15ZW1tdHBRWG04RUVyTWFaVWx0aHppaGxULTVUTElld2NRVEZHNkp4cmpTOEJNTzdrbTl5WGhfaU00UDVNQ0dUNmJDYjNDNVl0OHB5b0ZMTmowTXVJWXpyVXQ5Qkh4STM4b2EwX24tallkbw?oc=5","date":"2024-07-16","type":"pipeline","source":"Contract Pharma","summary":"Avalo Therapeutics Welcomes Chief Medical Officer - Contract Pharma","headline":"Avalo Therapeutics Welcomes Chief Medical Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE1nSHMzXzFGSlh0Tkg0OTlLREVUUmt4SWZCSlVDd1hHR3hXR2N5QTkxeDFGWURMZWNMNm9CUVBXQ2dKUS1kVklpV3FTczdHOTlyN2FicFZOV2sxZGVU?oc=5","date":"2021-08-27","type":"pipeline","source":"TradingView","summary":"AVTX Stock Price and Chart — NASDAQ:AVTX - TradingView","headline":"AVTX Stock Price and Chart — NASDAQ:AVTX","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxObHc5TnpKQ0Z6UHpBRjM2dEZPNE9tRDg3alI5X0w2WmNfN3ZFR05WYUM0ZzNrMGZkSElSbWppZGFqTHlmVWVRRXNjSmVGZEljYWdtV3BKN1pMeFhJNURDUnktZlRvMm1Cd1hlNnFiajNuakdPQ3BYTDdGLTRxY0JqTDItVHp3VnpMeDBmRVdfaE00U3dCSlZEbmhVSWIzTDBrRzRxVFotUmU4a0lTQ3l5bnhjdGpWRUJfUURiTTRCZW1ucENJZjY2amFzaXBMbV96c2dhVDZrWHZpa1E?oc=5","date":"2021-08-26","type":"pipeline","source":"globenewswire.com","summary":"Avalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc. - globenewswire.com","headline":"Avalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc.","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_2":5,"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}